Bcma-targeting chimeric antigen receptor and use thereof
AssigneeOricell Therapeutics Co., Ltd.
InventorsSiye CHEN, Yanhong XU, Hao GUO, Yue YANG, Huijiao LI, Zhifeng XU, Yanan SUN, Huanfeng YANG, Xiaowen HE
Life of this patent
Estimating the term…
Loading patent…
AssigneeOricell Therapeutics Co., Ltd.
InventorsSiye CHEN, Yanhong XU, Hao GUO, Yue YANG, Huijiao LI, Zhifeng XU, Yanan SUN, Huanfeng YANG, Xiaowen HE
Estimating the term…
A chimeric antigen receptor (CAR), containing a BCMA (B cell maturation antigen) binding domain. The BCMA binding domain includes an antibody or an antigen-binding fragment of an antibody that specifically binds to BCMA. The antibody contains a heavy-chain complementarity determining region 3 (HCDR3), a heavy-chain complementarity determining region 2 (HCDR2), and a heavy-chain complementarity determining region 1 (HCDR1). The HCDR3 contains an amino acid sequence as set forth in SEQ ID NO: 25, the HCDR2 contains an amino acid sequence as set forth in SEQ ID NO: 41, and the HCDR1 contains an amino acid sequence as set forth in SEQ ID NO: 21.
A chimeric antigen receptor (CAR), comprising a BCMA (B cell maturation antigen) binding domain,
(canceled)
4-6. (canceled)
8-17. (canceled)
21-26. (canceled)
29-33. (canceled)
36-37. (canceled)
40-43. (canceled)
46-53. (canceled)
(canceled)
(canceled)
59-64. (canceled)
66-67. (canceled)
69-74. (canceled)
76-86. (canceled)
Dependencies are inferred from the claim text.